

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1 to 20 (Cancelled).

21. (Previously presented) A vaccine comprising an HPV 16 L1 VLP, an HPV 18 L1 VLP, aluminium hydroxide and 3D MPL.

22. (Currently amended) A vaccine according to ~~claim 1~~ claim 21 wherein the VLPs are formulated using pre-adsorbed purified bulks of antigen or 3D MPL on aluminium hydroxide.

23. (Currently amended) A vaccine according to ~~claim 2~~ claim 22 wherein the ~~VLP 16 and VLP 18~~ HPV 16 L1 VLP and HPV 18 L1 VLP purified bulks are added to aluminium hydroxide to obtain a ratio of 2 µg VLP/10 µg aluminium hydroxide.

24. (Currently amended) The vaccine of ~~claim 1~~ claim 21 consisting of an HPV 16 L1 VLP, an HPV 18 L1 VLP, aluminium hydroxide and 3D MPL.

25. (Previously presented): An HPV 16 L1 VLP formulated with alum/3D-MPL using pre-adsorbed purified bulk of antigen or 3D MPL on aluminium hydroxide or aluminium phosphate.

26. (Previously presented): An HPV 18 L1 VLP formulated with alum/3D-MPL using pre-adsorbed purified bulk of antigen or 3D MPL on aluminium hydroxide or aluminium phosphate.